지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2024.9
- 수록면
- 837 - 846 (10page)
- DOI
- 10.4093/dmj.2024.0317
이용수
초록· 키워드
오류제보하기
People with type 2 diabetes mellitus (T2DM) are at higher risk of developing cardiovascular disease, heart failure, chronic kidney disease, and premature death than people without diabetes. Therefore, treatment of diabetes aims to reduce these complications. Sodium-glucose co-transporter 2 (SGLT2) inhibitors have shown beneficial effects on cardiorenal and metabolic health beyond glucose control, making them a promising class of drugs for achieving the ultimate goals of diabetes treatment. However, despite their proven benefits, the use of SGLT2 inhibitors in eligible patients with T2DM remains suboptimal due to reports of adverse events. The use of SGLT2 inhibitors is particularly limited in older patients with T2DM because of the lack of treatment experience and insufficient long-term safety data. This article comprehensively reviews the risk-benefit profile of SGLT2 inhibitors in older patients with T2DM, drawing on data from prospective randomized controlled trials of cardiorenal outcomes, original studies, subgroup analyses across different age groups, and observational cohort studies.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
제2형 당뇨병 환자에서 장기간의 Sodium-glucose Cotransporter 2 억제제 치료가 신장기능에 미치는 효과
대한내과학회지
2020 .08
-
Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: a Korean Diabetes Association and Korean Society of Nephrology consensus statement
Kidney Research and Clinical Practice
2020 .01
-
Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations
Diabetes and Metabolism Journal
2020 .01
-
Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors
Diabetes and Metabolism Journal
2019 .01
-
Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
Journal of Obesity & Metabolic Syndrome
2019 .01
-
SGLT2 억제제와 만성 콩팥병
대한내과학회지
2024 .04
-
Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Weight Reduction in Overweight and Obese Populations without Diabetes: A Systematic Review and a Meta-Analysis
Journal of Obesity & Metabolic Syndrome
2021 .12
-
Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Endocrinology and Metabolism
2021 .01
-
Off-target Effects of Sodium-glucose Cotransporter 2 (SGLT-2) Inhibitor in Cardiovascular Disease
Korean Circulation Journal
2020 .01
-
Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure
Korean Circulation Journal
2019 .01
-
새로운 심부전 약제, SGLT2 억제제
대한내과학회지
2023 .04
-
Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
Diabetes and Metabolism Journal
2021 .01
-
Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model
Korean Circulation Journal
2020 .01
-
Superior heart failure protecting effect of selective SGLT2 inhibitor than non-selective SGLT1,2 inhibitor in the diabetic heart failure zebrafish model
한국실험동물학회 학술발표대회 논문집
2022 .01
-
Metformin에 추가로 병용되는 SGLT2 inhibitors의 효능과 안전성에 관한 고찰
한국임상약학회지
2018 .01
-
Use of dapagliflozin in patients with advanced diabetic kidney disease
Kidney Research and Clinical Practice
2018 .01
-
SGLT2 Inhibitor, an Agent for Diabetes, Heart, Kidney… and Stroke
Korean Circulation Journal
2024 .09
-
Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment
Korean Circulation Journal
2021 .01
-
제2형 당뇨병 환자에서 Metformin과 병용한 Sodium-Glucose Cotransporter 2 Inhibitors와 Dipeptidyl Peptidase 4 Inhibitors의 효능 비교
병원약사회지
2020 .01
-
Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction
Korean Circulation Journal
2021 .01
최근 본 자료
댓글(0)
0